See more : Olympia Financial Group Inc. (OLY.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Candel Therapeutics, Inc. (CADL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Candel Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tele Columbus AG (TC1.DE) Income Statement Analysis – Financial Results
- Kichiri & Co., Ltd. (3082.T) Income Statement Analysis – Financial Results
- Shinyoungwacoal,Inc. (005800.KS) Income Statement Analysis – Financial Results
- Indraprastha Gas Limited (IGL.BO) Income Statement Analysis – Financial Results
- Innolux Corporation (3481.TW) Income Statement Analysis – Financial Results
Candel Therapeutics, Inc. (CADL)
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 125.00K | 125.00K | 125.00K | 125.00K |
| Cost of Revenue | 23.98M | 987.00K | 232.00K | 0.00 | 6.61M |
| Gross Profit | -23.98M | -862.00K | -107.00K | 125.00K | -6.48M |
| Gross Profit Ratio | 0.00% | -689.60% | -85.60% | 100.00% | -5,185.60% |
| Research & Development | 24.51M | 20.79M | 15.18M | 8.75M | 6.61M |
| General & Administrative | 13.72M | 14.06M | 10.67M | 5.18M | 2.56M |
| Selling & Marketing | 687.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.41M | 14.06M | 10.67M | 5.18M | 2.56M |
| Other Expenses | -24.51M | -48.00K | -1.08M | -624.00K | -571.00K |
| Operating Expenses | 14.41M | 34.80M | 24.78M | 13.31M | 8.59M |
| Cost & Expenses | 38.39M | 34.80M | 24.78M | 13.31M | 8.59M |
| Interest Income | 0.00 | 490.00K | 53.00K | 111.00K | 1.07M |
| Interest Expense | 514.00K | 490.00K | 53.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 960.00K | 987.00K | 232.00K | 91.00K | 43.00K |
| EBITDA | -37.43M | -17.32M | -25.49M | -13.72M | -8.20M |
| EBITDA Ratio | 0.00% | -40,835.20% | -19,534.40% | -6,792.00% | -6,063.20% |
| Operating Income | -38.39M | -34.72M | -25.73M | -13.81M | -9.04M |
| Operating Income Ratio | 0.00% | -27,777.60% | -20,580.80% | -11,048.00% | -7,229.60% |
| Total Other Income/Expenses | 452.00K | 15.93M | -10.40M | -3.87M | 797.00K |
| Income Before Tax | -37.94M | -18.79M | -36.12M | -17.68M | -8.24M |
| Income Before Tax Ratio | 0.00% | -15,035.20% | -28,899.20% | -14,144.00% | -6,592.00% |
| Income Tax Expense | 0.00 | -15.93M | 53.00K | 4.49M | -226.00K |
| Net Income | -37.94M | -2.87M | -36.18M | -22.17M | -8.01M |
| Net Income Ratio | 0.00% | -2,292.80% | -28,941.60% | -17,739.20% | -6,411.20% |
| EPS | -1.31 | -0.10 | -1.26 | -0.76 | -0.27 |
| EPS Diluted | -1.31 | -0.10 | -1.26 | -0.76 | -0.27 |
| Weighted Avg Shares Out | 28.94M | 28.82M | 28.69M | 29.15M | 29.15M |
| Weighted Avg Shares Out (Dil) | 28.94M | 28.82M | 28.69M | 29.15M | 29.15M |
Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters' Option
Candel Therapeutics Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports